Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting

Methods in Molecular Biology

Volumn 1172, Issue , 2014, Pages 271-283

  Gatla, Himavanth R ^a   Singha, Bipradeb ^a   Persaud, Valerie ^a   Vancurova, Ivana ^a  

^a NONE

Author keywords

Bortezomib; HMGB1; IL 8; Nuclear localization; Ovarian cancer; Prostate cancer

Indexed keywords

CYTOPLASM PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 8; NUCLEAR PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DRUG MIXTURE; HMGB1 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; PYRAZINE DERIVATIVE;

ARTICLE; CANCER CELL; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL FRACTIONATION; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DRUG EFFECTS; DRUG MIXTURE; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CELL FRACTIONATION; CELL LINE, TUMOR; CELL NUCLEUS; COMPLEX MIXTURES; CYTOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE EXPRESSION; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-8; MALE; PYRAZINES;

EID: 84922482110     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0928-5_25     Document Type: Article

References (24)

1. Xu L, Fidler IJ (2000) Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 12:97–106
2. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735–6741
3. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539–545
4. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550
5. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444
6. Araki S, Omori Y, Lyn D et al (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67:6854–6862
7. Singh RK, Lokeshwar BL (2011) The IL-8- regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 71:3268–3277
8. Chen J, Xi B, Zhao Y et al (2012) Highmobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126:109–117
9. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195
10. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342
11. Bell CW, Jiang W, Reich CF III et al (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291:1318–1325
12. Sha Y, Zmijewski J, Xu Z et al (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180:2531–2537
13. Tang D, Kang R, Cheh CW et al (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29:5299–5310
14. Tang D, Kang R, Livesey KM et al (2010) Endogenous HMGB1 regulates autophagy. J Cell Biol 190:881–892
15. Gnanasekar M, Kalyanasundaram R, Zheng G et al (2013) HMGB1: a promising therapeutic target for prostate cancer. Prostate Cancer 2013:1–8
16. Chen J, Liu X, Zhang J et al (2012) Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol 227:3629–3638
17. Lu B, Nakamura T, Inouye K et al (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488:670–674
18. Lu B, Wang H, Andersson U et al (2013) Regulation of HMGB1 release by inflammasomes. Protein Cell 4:163–167
19. Yang H, Antoine DJ, Andersson U et al (2013) The many faces of HMGB1: molecular structurefunctional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93:865–873
20. Guo ZS, Liu Z, Bartlett DL et al (2013) Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res 3:1–20
21. Li W, Zhu S, Li J et al (2011) EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 81:1152–1163
22. Manna S, Singha B, Phyo SA et al (2013) Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. J Immunol 191:2837–2846
23. Singha B, Gatla H, Manna S et al (2014) Proteasome inhibition increases recruitment of IKKβ, S536P-p65 and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 289: 2687–2700
24. Miskolci V, Ghosh CC, Rollins J et al (2006) TNFα release from peripheral blood leukocytes depends on a CRM1-mediated nuclear export. Biochem Biophys Res Commun 351:354–360